Business, energy, technology, markets and global industry news from Business News Today

Fibronectin-EDB

PharmaDeviceNews Fibronectin-EDB
FairJourney Bio’s antibody engineering work is advancing a tumor-conditional IL-12 approach designed to activate potent cytokine signaling more selectively within the tumor microenvironment, potentially addressing one of IL-12 therapy’s longstanding toxicity challenges. Representative image.
Pharma & Biotech

Can FairJourney Bio’s reversible antibody switch solve IL-12’s decades-old toxicity problem?

FairJourney Bio engineers a tumor-conditional IL-12 switch designed to limit systemic exposure and localize cytokine activation in solid tumors.

Read More